Depression Clinical Trial
Official title:
Predictors and Mechanisms of Depression and Anxiety During the COVID-19 Pandemic
Study description:
The present study seeks to investigate the predictors and maintaining mechanisms of
depression and anxiety symptoms during the COVID-19 pandemic, exactly 3 months following the
strictest viral mitigation strategies initiated in Norway in response to the pandemic. This
is the time period where the major pandemic protocols are lifted in Norway, following three
months of strict pandemic mitigation protocols. The study further aims to identify subgroups
with highest levels of depressive and anxiety symptoms during the measurement period, to
identify vulnerable subgroups with maintained symptoms three months following the pandemic.
Hypotheses and research questions:
Research Question 1: What is the level of depressive and anxiety symptoms three months
following the employment of the strict viral mitigation protocols (i.e., physical distancing
protocols) in the general adult population? What are the proportion above the validated
cut-offs for depression and general anxiety? Hypothesis 1: There will be a significant
decrease in the levels of depression and anxiety symptoms from the baseline (T1) with the
strictest mitigation protocols to measurement the measurement period three months into
pandemic (T2) where major pandemic mitigation protocols are lifted. Additionally, there will
be a significant decrease in the proportion of the sample meeting validated cut-offs for
depression and anxiety from T1 to T2.
Hypothesis 2: Higher level at T1 and less reduction from T1 to T2 in positive metacognitions,
negative metacognitions, and unhelpful coping strategies all measured with CAS-1, will be
related to less reduction in depression and anxiety, above and beyond age, gender, and
education. Higher level at T1 and increases from T1 to T2 in physical activity and perceived
competence will be related to greater reduction in depression and anxiety, above and beyond,
age, gender, and education.
Exploratory: The investigators will further explore the proportion showing reliable change in
depression and anxiety and investigate the differences in changes in depression and anxiety
across different demographic subgroups in the sample
Status | Not yet recruiting |
Enrollment | 4000 |
Est. completion date | July 13, 2020 |
Est. primary completion date | July 13, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Eligible participants are all adults including those of 18 years and above, - Who are currently living in Norway and thus experiencing identical viral mitigation protocols, and - Who provide digital consent to partake in the study. Exclusion Criteria: - Children and adolescents (individuals below 18) - Adults not residing in Norway during the measurement period |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Oslo | Modum Bad |
Johnson SU, Ulvenes PG, Øktedalen T, Hoffart A. Psychometric Properties of the General Anxiety Disorder 7-Item (GAD-7) Scale in a Heterogeneous Psychiatric Sample. Front Psychol. 2019 Aug 6;10:1713. doi: 10.3389/fpsyg.2019.01713. eCollection 2019. — View Citation
Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13. — View Citation
Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Patient Health Questionnaire 9 | • The Patient Health Questionnaire 9 (PHQ-9; Kroenke, Spitzer & Williams, 2001) is used to measure symptoms of depression in accordance with the diagnostic criteria for major depressive disorder. The questionnaire consists of nine items where each is scored on a four-point Likert scale (0-3), with the range of scores from 0 to 27. Higher scores indicate greater depression severity, and scores above 10 are considered as the cut-off that indicating that the patient is within the depressive area. | Data is set to be collected starting from 22nd of June until enough data has been collected.The data collection period will last no longer than three weeks. | |
Primary | Generalized Anxiety Disorder 7 | • The Generalized Anxiety Disorder 7 (GAD-7; Spitzer, Kroenke, Williams & Löwe, 2006) is a questionnaire consisting of seven items measuring symptoms of anxiety and worry. The items are scored on a four-point Likert scale (0-3), with the scores ranging from 0 to 21. Specific cut-off for Norwegian samples have been found yielding a cut-off of 8 and above for high sensitivity and specificity (Johnson, Ulvenes, Øktedalen & Hoffart, 2019). | Data is set to be collected starting from 22nd of June until enough data has been collected.The data collection period will last no longer than three weeks. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05777044 -
The Effect of Hatha Yoga on Mental Health
|
N/A | |
Recruiting |
NCT04977232 -
Adjunctive Game Intervention for Anhedonia in MDD Patients
|
N/A | |
Recruiting |
NCT04680611 -
Severe Asthma, MepolizumaB and Affect: SAMBA Study
|
||
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Completed |
NCT04512768 -
Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Completed |
NCT04476446 -
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
|
Phase 3 | |
Recruiting |
NCT02783430 -
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
|
Phase 2/Phase 3 | |
Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
Completed |
NCT04598165 -
Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support
|
N/A | |
Completed |
NCT03457714 -
Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
|
||
Recruiting |
NCT05956912 -
Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
|
||
Completed |
NCT05588622 -
Meru Health Program for Cancer Patients With Depression and Anxiety
|
N/A | |
Recruiting |
NCT05234476 -
Behavioral Activation Plus Savoring for University Students
|
N/A | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Enrolling by invitation |
NCT03276585 -
Night in Japan Home Sleep Monitoring Study
|
||
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A |